2cureX (2CUREX) Investor Update summary

Board and leadership changes

• Two new board members, Nat Hutley and Dan Honeywell, were elected, bringing expertise in med tech, biotech, and oncology diagnostics to support a transformation and new commercial platform.

• The new board members aim to help reposition the company for growth in precision oncology diagnostics.

Company restructuring and asset sale

• The company split into two entities: the Swedish-listed company and the Danish subsidiary with its German branch, each with distinct business models.

• Ernst & Young valued the company at SEK 5.6 million, and shareholders approved the sale of the Danish-German subsidiary to a consortium including new board members and existing shareholders.

• Proceeds from the sale will be distributed to shareholders pro rata, pending a new general meeting for final approval.

Commercial strategy and business model update

• The previous distributor-based commercial model was identified as a key reason for underperformance; a direct-to-patient model is now planned.

• The new strategy focuses on automation, scalability, and direct engagement with patients, aiming to consolidate and grow in precision oncology.

• The company will use its market knowledge, hospital contacts, and survey data to support the new commercial approach.